BioChemics & Beth Israel Deaconess Medical Center Announce Wound Healing Research...

Tue Apr 8, 2008 4:39pm EDT

[-] Text [+]

BioChemics & Beth Israel Deaconess Medical Center Announce Wound Healing Research Collaboration

DANVERS, Mass.--(Business Wire)--
BioChemics, Inc., a company "pioneering transdermal drug
delivery," announced it has entered into a research collaboration with
Beth Israel Deaconess Medical Center (BIDMC) to evaluate the wound
healing effects of some of the Company's novel, proprietary
formulations in preclinical models. BIDMC is one of the largest, most
respected research hospitals in the country. BioChemics is a
pharmaceutical company that has developed a novel, transdermal drug
delivery system that for the first time may allow almost any drug to
be efficiently delivered through the skin. The transdermal technology,
called VALE(R) (Vaso-active Lipid Encapsulated), may allow a
substantial portion of the pharmacopeia to be re-engineered, turning
oral drugs into transdermals that are safer (no gastro-intestinal
problems), cheaper and potentially faster acting (applied directly to
the treated area) than oral equivalents.

Recent industry reports estimate the global wound care market to
approach $12 billion by 2009, with a yearly growth rate in excess of
7%. US markets account for approximately half of the spending in this
area. Indications for wound therapy and management include diabetes,
age related skin or pressure ulcers, trauma and surgery.(1)

"Collaborating with BIDMC represents an exciting opportunity to
partner with a premier academic hospital to further explore the use of
our novel transdermal drug delivery formulations to treat wound
healing," said John J. Masiz., President & CEO, BioChemics, Inc. "We
continue to develop new transdermal delivery systems that target a
variety of inflammatory and peripheral diseases."

"The area of wound healing is generating great interest and I look
forward to working again with BioChemics, Inc.," said Dr. Aris Veves,
Joslin-Beth Israel Deaconess Foot Center, Associate Professor in
Surgery, Harvard Medical School.

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching
and research affiliate of Harvard Medical School, and consistently
ranks in the top four in National Institutes of Health funding among
independent hospitals nationwide. BIDMC is clinically affiliated with
the Joslin Diabetes Center and is a research partner of
Dana-Farber/Harvard Cancer Care Center. BIDMC is the official hospital
of the Boston Red Sox. For more information, visit
www.bidmc.harvard.edu.

Dr. Aris Veves, Research Director, Joslin-Beth Israel Deaconess
Foot Center, Associate Professor in Surgery , Harvard Medical School

Dr. Veves' areas of expertise include diabetic neuropathy,
diabetic foot problems, and vascular reactivity. His main academic
interest is the vascular reactivity of micro- and macrocirculation and
in the past two years, he has served as Director of the
Microcirculation Lab, which tests microvasculature in a non-invasive
way. He is also interested in the etiology of diabetic foot problems
and the pathophysiology of wound healing in diabetes. Other interests
include the effect of c-nociceptive fiber dysfunction of wound healing
and the diabetes-related impairment of angiogenesis.

Dr. Aristidis Veves received his M.D. from the Medical School,
Aristotelion / University of Thessaloniki (Greece), his M.Sc. from the
Faculty of Medicine, University of Manchester (U.K.), and his D.Sc.
from Athens Medical School (Greece). Dr. Veves did his internship in
General Medicine at Athens Naval Hospital (Greece), and completed his
residency in General Medicine at Tsaggari General District Hospital
(Athens, Greece). He then served as Hon. Senior House Officer in the
University Department of Medicine, Diabetes and Endocrinology at
Manchester Royal Infirmary (U.K.). Following this, he was a Clinical
Research Fellow in the same department. Most recently, he was a
Research Fellow at Deaconess - Joslin Foot Center, Deaconess Hospital
(Boston, MA).

About BioChemics, Inc.

BioChemics is a pharmaceutical company that has developed a novel,
transdermal drug delivery system for the first time that allows almost
any drug to be efficiently delivered through the skin. The transdermal
technology, called VALE(R) (Vaso-active Lipid Encapsulated), allows a
substantial portion of the pharmacopeia to be re-engineered, turning
oral drugs into transdermals that are safer (no gastro-intestinal
problems), cheaper and potentially faster acting (applied directly to
the treated area) than oral equivalents. The company's focus is on
multi-billion dollar market opportunities currently underserved by
existing therapies. The company's two lead clinical products focus on
treating diabetic neuropathy and osteoarthritis. Founded in 1989, the
Company is headquartered in Danvers, Mass. Additional information is
available at www.biochemics.com.

VALE(R) is a registered trademark of BioChemics, Inc.

(1) Source: www.Nerac.com, posted 05/12/2006.

BioChemics, Inc.
David H. Donabedian, Ph.D., 978-750-0090
COO & SVP, Business Development